Topoisomerase II alpha as a marker predicting anthracyclines’ activity in early breast cancer patients: Ready for the primetime?

This publication has 29 references indexed in Scilit:

• Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer
  New England Journal of Medicine, 2006
• Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
  Journal of Clinical Oncology, 2006
• Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
  Journal of Clinical Oncology, 2005
• Identification and validation of prognostic markers in breast cancer with the complementary use of array‐CGH and tissue microarrays
  The Journal of Pathology, 2005
• Human topoisomerase IIα nuclear export is mediated by two CRM-1-dependent nuclear export signals
  Journal of Cell Science, 2004
• Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
  Genes, Chromosomes and Cancer, 2004
• Influence of Cell Cycle and Oncogene Activity upon Topoisomerase IIα Expression and Drug Toxicity
  Molecular and Cellular Biology, 2000
• Ectopic expression of human topoisomerase IIα fragments and etoposide resistance in mammalian cells
  International Journal of Cancer, 2000
• Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation
  Gene, 2000
• DNA Topoisomerase II-Alpha Immunoreactivity as a Marker of Tumor Aggressiveness in Invasive Breast Cancer
  Pathobiology, 2000